For income-focused investors, amgen stock (NASDAQ: AMGN) has historically been a reliable, defensive anchor. But as we move through 2026, the narrative surrounding this biotechnology pioneer is shifting dramatically from a low-growth dividend play to an aggressive, high-upside biopharma story. With a current share price hovering around $337, Wall Street is intensely debating whether Amgen's pipeline—spearheaded by its revolutionary obesity drug candidate MariTide—can offset the impending patent cliffs of its legacy portfolio. This deep-dive analysis breaks down Amgen's financial performance, its therapeutic pipeline, its valuation, and whether amgen stock is a buy, sell, or hold for long-term portfolios.
Amgen's Q1 2026 Earnings & Raised Guidance: Financial Strength Revealed
On April 30, 2026, Amgen announced its first-quarter financial results, delivering a strong performance that beat consensus estimates and set a positive tone for the rest of the fiscal year. Total revenues for the quarter rose 6% year-over-year to $8.62 billion, edging past Wall Street forecasts of $8.55 billion. This revenue growth was primarily driven by strong volume demand across its core commercial portfolio, demonstrating that Amgen's underlying business remains highly resilient even as it navigates structural changes in the global healthcare market.
On the earnings front, non-GAAP diluted earnings per share (EPS) grew 5% to $5.15, comfortably surpassing the average analyst projection of $4.76. GAAP EPS climbed 4% to $3.34, reflecting higher operating income that was partially offset by minor, non-cash unrealized losses on equity investments. The company's profitability profile remains incredibly robust. GAAP operating margin expanded by an impressive 17.4 percentage points to 32.4%, while non-GAAP operating margin hovered at a highly efficient 45.3%.
Crucially, Amgen's management felt confident enough in the company's trajectory to raise its full-year 2026 guidance. The company now projects total revenues to land between $37.1 billion and $38.5 billion (up from the previous range of $37.0 billion to $38.4 billion) and raised its non-GAAP EPS expectations to a range of $21.70 to $23.10.
This raised outlook is particularly impressive because it reflects the business's ability to maintain high margins while simultaneously increasing its research and development (R&D) and capital expenditure allocations. For example, Amgen generated $1.5 billion in free cash flow in Q1 2026 compared to $1.0 billion in Q1 2025. This cash flow is actively being redeployed. Amgen is expanding its advanced manufacturing footprint, including a $650 million investment in its Juncos, Puerto Rico, biomanufacturing facility to scale up production and strengthen global supply chain resilience. This financial discipline is a major reason why institutional investors continue to view amgen stock as a foundational holding.
The Obesity Disruption: Decoding the MariTide Advantage
While Amgen's current financials are supported by its approved medications, the primary driver of excitement for amgen stock is its clinical pipeline, specifically its investigational obesity and type 2 diabetes treatment, MariTide (maridebart cafraglutide, formerly AMG 133). The global weight loss market has been dominated by Eli Lilly (Zepbound) and Novo Nordisk (Wegovy), but Amgen is positioning MariTide as a highly differentiated, potential "best-in-class" alternative.
To understand MariTide's potential, we must look at how it works. Existing treatments like Wegovy are glucagon-like peptide-1 (GLP-1) receptor agonists, while Zepbound is a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. MariTide takes a different structural approach: it is an antibody-peptide conjugate (APC) that activates the GLP-1 receptor but antagonizes (blocks) the GIP receptor.
This unique biological mechanism of action is designed to offer two major clinical advantages:
- More Durable Weight Loss: Phase 2 clinical data released in late 2024 showed that MariTide achieved up to approximately 20% weight loss at 52 weeks. More importantly, early data suggests that weight loss may be more durable, with patients maintaining their weight reduction even after discontinuing or reducing the frequency of treatment.
- Dosing Convenience: While current obesity blockbusters require weekly self-injections, Amgen is developing MariTide with once-monthly or even once-quarterly dosing schedules. At the 2026 J.P. Morgan Healthcare Conference, CEO Robert Bradway highlighted this extended dosing interval as a potential paradigm shift in obesity care, drastically improving patient compliance and lifestyle convenience.
Amgen's Phase 3 clinical program for MariTide, named MARITIME, is one of the largest and most accelerated clinical trial campaigns in the company’s 45-year history. It includes several key studies:
- MARITIME-1: Evaluating chronic weight management in adults living with obesity or overweight without type 2 diabetes.
- MARITIME-2: Assessing weight management in patients with type 2 diabetes.
- MARITIME-CV: Tracking long-term cardiovascular outcomes in obese patients with established atherosclerotic cardiovascular disease.
- MARITIME-HF: Evaluating patients with heart failure.
- MARITIME-SWITCH: This recently accelerated trial is particularly vital. It studies the safety and efficacy of transitioning patients who are currently on weekly injectable GLP-1 therapies over to MariTide. If successful, this trial will allow Amgen to capture a massive market share of patients seeking to switch from weekly shots to monthly or quarterly maintenance dosing.
If the Phase 3 MARITIME trials deliver positive readouts, MariTide could easily become a multi-billion dollar commercial engine, driving a massive upward re-rating of amgen stock.
Beyond Obesity: Amgen's Oncology and Rare Disease Powerhouses
While the media focus remains heavily on MariTide, a critical content gap in many competitor analyses is the strength of Amgen's broader clinical and commercial portfolio. Amgen is not a one-trick pony; it has a deeply diversified commercial engine with 14 products that each generate over $1 billion in annualized sales.
The Oncology Renaissance: IMDELLTRA & LUMAKRAS
Amgen is aggressively expanding its oncology footprint with innovative immunotherapies. A standout success is IMDELLTRA (tarlatamab), a bispecific T-cell engager (BiTE) targeting delta-like ligand 3 (DLL3). Fully approved for second-line extensive-stage small cell lung cancer (SCLC), IMDELLTRA has seen rapid, widespread adoption. By early 2026, the therapy was being administered at more than 1,600 clinical sites across the United States. Amgen is currently advancing three additional Phase 3 trials to move IMDELLTRA into first-line treatment and maintenance settings, significantly expanding its long-term addressable market.
Additionally, LUMAKRAS (sotorasib) continues to advance in clinical trials, moving into earlier-line settings for non-small cell lung cancer (NSCLC) and colorectal cancer, while xaluritamig is showing massive promise in pivotal prostate cancer trials.
Established Cardiovascular and Immunology Blockbusters
- Repatha (evolocumab): This PCSK9 inhibitor has become an absolute juggernaut, surpassing $3 billion in annual sales in 2025. Driven by expanding global cardiovascular guidelines and a 44% surge in new-to-brand U.S. prescriptions, Repatha continues to grow at a double-digit rate.
- Tezspire (tezepelumab-ekko): Co-developed with AstraZeneca, this severe asthma medication continues to perform exceptionally well, posting growth rates exceeding 30% year-over-year as it expands into broader patient populations.
- Evenity (romosozumab): This bone-building therapy for osteoporosis remains a high-growth asset, providing steady, high-margin cash flow.
Rare Disease Integration: Horizon Therapeutics
Amgen's $27.8 billion acquisition of Horizon Therapeutics in late 2023 is paying off handsomely. The integration has added high-value, first-in-class rare disease assets to Amgen's commercial portfolio, such as TEPEZZA (for thyroid eye disease) and KRYSTEXXA (for chronic refractory gout). Furthermore, UPLIZNA, a twice-yearly antibody treatment for neuromyelitis optica spectrum disorder (NMOSD), grew an outstanding 73% in 2025 to reach $655 million in sales, highlighting the commercial synergy of plugging Horizon's pipeline into Amgen's global sales infrastructure.
The Bear Case: Biosimilar Erosion, Debt, and Transition Risks
To write a truly complete analysis of amgen stock, we must address the headwinds and structural risks that bullish competitors often gloss over. Investing in biotechnology always carries risk, and Amgen is currently facing three major challenges:
1. The Prolia/Xgeva Patent Cliff
Amgen's bone-density blockbuster Prolia (and its oncology counterpart, Xgeva) has been a foundational cash cow for the company. However, Prolia is facing key patent expirations and imminent biosimilar competition in late 2026. This creates a multi-billion dollar revenue hole that Amgen's newer therapies must fill. While management has factored this headwind into their 2026 guidance, biosimilar erosion of a legacy cash cow represents a highly visible drag on near-term revenue growth.
2. The Inflation Reduction Act (IRA) and Pricing Pressures
Biopharma companies are operating in an increasingly challenging regulatory environment. In its Q1 2026 earnings report, Amgen noted that its product sales volume growth of 9% was partially offset by a 2% lower net selling price. This pricing decline was driven directly by the implementation of U.S. Medicare Part D price-setting under the Inflation Reduction Act (effective January 1, 2026), alongside an increased 340B Program mix. Government-mandated pricing pressures are a systemic risk that will continue to squeeze margins across the entire pharmaceutical sector.
3. A Heavy Debt Load
To fund the Horizon Therapeutics acquisition, Amgen took on a significant amount of leverage. While the company retired a massive $6.0 billion of debt in 2025 (on top of $4.5 billion in 2024), it still carried $57.3 billion in outstanding debt against $12.0 billion in cash as of March 31, 2026. While Amgen’s high cash-generation capacity makes this debt manageable, servicing this leverage restricts the company's ability to engage in aggressive share buybacks (which are capped at $3.0 billion for 2026) and requires disciplined capital allocation.
4. Leadership Transitions
In May 2026, Amgen announced that long-serving Chief Financial Officer Peter Griffith will retire. Thomas Dittrich, a highly experienced finance leader who previously held executive roles at Galderma and Shire, will rejoin the company on July 1, 2026, and officially assume the CFO position on September 1, 2026. While Griffith will remain with the company through January 2027 to ensure a seamless transition, a change in financial leadership at a time of high R&D spend and debt paydown adds a minor layer of execution uncertainty that investors must monitor closely.
Amgen Stock Valuation & Dividend Analysis: The Math for Investors
At a trading price of approximately $337 per share, amgen stock presents a compelling valuation proposition, particularly for value-oriented and dividend-growth investors.
Dividend Reliability
Amgen is a member of the Dow Jones Industrial Average and has built an exceptional track record of returning capital to shareholders. The company declared a $2.52 per share dividend for both the first and second quarters of 2026. This translates to an annualized dividend payout of $10.08 per share, yielding approximately 3.0% at current trading levels. Over the past five years, Amgen has grown its dividend at an average annual rate of roughly 7.7%. This reliable, growing yield provides a highly defensive floor for the stock, paying investors to wait while the company’s high-growth pipeline matures.
Multiples and Analyst Forecasts
Amgen trades at a trailing price-to-earnings (P/E) ratio of roughly 22.8x. While this sits slightly above the average for low-growth generic pharmaceutical companies, it is a massive discount compared to high-growth biotech and weight-loss competitors (which often trade at earnings multiples north of 35x or even 50x). Discounted Cash Flow (DCF) models that incorporate conservative assumptions for MariTide’s commercialization peg Amgen's intrinsic value well above $400 per share, suggesting the stock is trading at a discount to its long-term potential.
Wall Street analysts currently maintain a neutral-to-bullish consensus on the stock, with a median 12-month price target of $352.50. High-end estimates reach up to $427.00, representing substantial upside if MariTide's Phase 3 data reads out positively later in the year.
Frequently Asked Questions (FAQ)
What is the current dividend yield for Amgen stock?
As of May 2026, Amgen pays a quarterly dividend of $2.52 per share, which equates to an annualized payout of $10.08. At a share price of roughly $337, this represents a trailing dividend yield of approximately 3.0%.
How does Amgen's obesity drug MariTide differ from Wegovy and Zepbound?
Unlike Wegovy (which activates GLP-1) and Zepbound (which activates both GLP-1 and GIP), MariTide is an antibody-peptide conjugate that activates the GLP-1 receptor while blocking (antagonizing) the GIP receptor. This unique mechanism is designed to provide more durable weight loss and allows for once-monthly or once-quarterly dosing, compared to the weekly injections required by Wegovy and Zepbound.
When does the new CFO take over at Amgen?
Thomas Dittrich will return to Amgen on July 1, 2026, and will officially assume the Executive Vice President and CFO role on September 1, 2026. The retiring CFO, Peter Griffith, will stay with the company until January 2027 to ensure a smooth, structured transition.
What are the main risks facing Amgen stock in 2026?
Amgen's primary risks include impending biosimilar competition for its bone-density drug Prolia in late 2026, systemic pricing pressures from the U.S. Inflation Reduction Act (Medicare Part D price setting), and a substantial debt load of $57.3 billion from the Horizon Therapeutics acquisition.
Conclusion
Amgen stock represents a unique hybrid opportunity in today's market. It functions as a stable, defensive income generator yielding 3% with a diversified commercial portfolio of blockbusters like Repatha, Tezspire, and its newly integrated Horizon rare disease therapies. Yet, it also possesses a high-growth lottery ticket in MariTide, which has the potential to disrupt the multi-billion dollar obesity market with its convenient monthly-to-quarterly dosing schedules.
For investors seeking a balance of safety, growing dividends, and explosive pipeline optionality, Amgen at ~$337 is an exceptionally attractive long-term addition to a diversified portfolio. While patent cliffs and regulatory pricing pressures remain real challenges, Amgen's superb cash generation, robust margins, and proven commercial execution suggest the company is well-prepared to navigate these headwinds and unlock its next major growth cycle.
